ProMIS Neurosciences Inc PMN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Shares Outstanding
- 8.97M
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 11
Valuation
|
Metric
|
PMN
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.57 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
PMN
|
|---|---|
Quick Ratio | 7.44 |
Current Ratio | 7.85 |
Interest Coverage | — |
Quick Ratio
PMN
Profitability
|
Metric
|
PMN
|
|---|---|
Return on Assets (Normalized) | −125.50% |
Return on Equity (Normalized) | −175.20% |
Return on Invested Capital (Normalized) | −175.20% |
Return on Assets
PMN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|gC%Wq@ | LOCK|#<s?S | $129B | |||
| Moderna Inc
MRNA
| LOCK|Fh&F^q | LOCK|%@ | $85B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|?Ds<<&X | LOCK|%lw< | $79B | |||
| argenx SE ADR
ARGX
| LOCK|>>wMgZ | LOCK|lr | $52B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|$Tl<%^ | LOCK|^N | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|$Yz$Q# | LOCK|K!<^r | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|%?!TvG% | LOCK|&!S%^ | $26B | |||
| BioNTech SE ADR
BNTX
| LOCK|?YH>xt | LOCK|ff& | $24B | |||
| Incyte Corp
INCY
| LOCK|!?VjNv | LOCK|M$ | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|HD%JFm? | LOCK|qY# | $14B |
United States